TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
-5.63%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.54B
AUM Growth
+$2.54B
(-11%)
Cap. Flow
-$63M
Cap. Flow
% of AUM
-2.48%
Top 10 Holdings %
Top 10 Hldgs %
38.38%
Holding
180
New
5
Increased
28
Reduced
33
Closed
3
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$14.8M |
| 2 |
Intuitive Surgical
ISRG
|
$9.75M |
| 3 |
AstraZeneca
AZN
|
$8.86M |
| 4 |
SPDR S&P Biotech ETF
XBI
|
$8.43M |
| 5 |
Boston Scientific
BSX
|
$8.42M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$24M |
| 2 |
McKesson
MCK
|
$14.8M |
| 3 |
Eli Lilly
LLY
|
$11.5M |
| 4 |
Medtronic
MDT
|
$9.78M |
| 5 |
Waters Corp
WAT
|
$8.23M |
Sector Composition
| 1 | Healthcare | 95.42% |
| 2 | Real Estate | 3.13% |
| 3 | Industrials | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
UnitedHealth
UNH
$281B
| $164M | 6.45% | 319,510 -10,516 | -3% | -$5.4M |
|
2
Amgen
AMGN
$155B
| $133M | 5.24% | 548,418 -26,500 | -5% | -$6.45M |
|
3
Gilead Sciences
GILD
$140B
| $102M | 4.01% | 1,650,765 -35,800 | -2% | -$2.21M |
|
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $102M | 4% | 361,231 +52,347 | +17% | +$14.8M |
|
5
Johnson & Johnson
JNJ
$427B
| $91.7M | 3.6% | 516,652 | – | – |
|
6
AbbVie
ABBV
$372B
| $86.8M | 3.41% | 566,842 +18,698 | +3% | +$2.86M |
|
7
Regeneron Pharmaceuticals
REGN
$61.5B
| $84.5M | 3.32% | 142,864 -3,336 | -2% | -$1.97M |
|
|
8
AstraZeneca
AZN
$248B
| $74.3M | 2.92% | 1,124,741 +134,066 | +14% | +$8.86M |
|
|
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $69.9M | 2.75% | 876,089 -83,350 | -9% | -$6.65M |
|
10
Abbott
ABT
$231B
| $68.2M | 2.68% | 627,292 +8,515 | +1% | +$925K |
|
11
Bristol-Myers Squibb
BMY
$96B
| $60.3M | 2.37% | 782,735 +58,859 | +8% | +$4.53M |
|
12
Pfizer
PFE
$141B
| $59.4M | 2.33% | 1,132,103 -39,800 | -3% | -$2.09M |
|
|
13
Eli Lilly
LLY
$657B
| $57.2M | 2.25% | 176,432 -35,400 | -17% | -$11.5M |
|
14
Thermo Fisher Scientific
TMO
$186B
| $53M | 2.08% | 97,605 | – | – |
|
|
15
McKesson
MCK
$85.4B
| $52.4M | 2.06% | 160,722 -45,300 | -22% | -$14.8M |
|
16
Merck
MRK
$210B
| $50.3M | 1.98% | 552,122 -23,500 | -4% | -$2.14M |
|
17
Moderna
MRNA
$9.37B
| $46.9M | 1.84% | 328,524 | – | – |
|
18
Cigna
CI
$80.3B
| $45.6M | 1.79% | 173,106 +1,083 | +0.6% | +$285K |
|
19
Stryker
SYK
$150B
| $44.9M | 1.76% | 225,678 | – | – |
|
20
Illumina
ILMN
$15.8B
| $36.1M | 1.42% | 196,047 -30,165 | -13% | -$5.56M |
|
|
SGEN
21
DELISTED
Seagen Inc. Common Stock
SGEN
| $34.5M | 1.36% | 195,183 -135,378 | -41% | -$24M |
|
22
Danaher
DHR
$147B
| $31.6M | 1.24% | 124,556 -25,589 | -17% | -$6.49M |
|
23
Humana
HUM
$36.5B
| $29.9M | 1.17% | 63,794 +234 | +0.4% | +$110K |
|
|
24
Boston Scientific
BSX
$156B
| $29.6M | 1.16% | 795,215 +225,817 | +40% | +$8.42M |
|
25
Molina Healthcare
MOH
$9.8B
| $29.4M | 1.15% | 105,085 +10,560 | +11% | +$2.95M |
|